Autonomix Medical, Inc. reported a net loss of $5.85 million for the six months ended September 30, 2026, an improvement from the $10.79 million loss in the prior year period. The company strengthened its balance sheet through warrant exercises, ending the period with $7.69 million in cash and cash equivalents while continuing to develop its proprietary catheter-based sensing and RF ablation technologies.
Autonomix Medical held its 2026 Annual Meeting of Stockholders on October 29, 2026, where shareholders elected six directors and ratified Forvis Mazars, LLP as the independent auditor. Stockholders also approved an amendment to the 2023 Stock Plan to increase authorized shares by 750,000 and granted the Board authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-25.
Autonomix Medical has appointed Sandra Kalter, the former Chief Regulatory Counsel and Vice President of Medtronic, to its Board of Directors, increasing the board size from five to six members. Ms. Kalter brings over 40 years of MedTech experience, including regulatory strategy and M&A due diligence for major medical device platforms. She will participate in the company's standard compensation program for non-employee directors.